Eli Lilly and Company will invest EUR 35 million ($40 million) in delivering a new manufacturing facility using continuous manufacturing technology at its campus in Kinsale, Ireland, according to IDA Ireland, a non-commercial, semi-state organization for economic development in Ireland. 

The facility will be used to carry out the development and commercialization of a number of Lilly's small-molecule pipeline products that are currently undergoing late-stage clinical trials. The facility is targeted to be fully operational by early 2017. This development will see the Kinsale site becoming the center of excellence for continuous manufacturing for active pharmaceutical ingredients (APIs) for Lilly worldwide.

This investment follows a major biotech investment program at Kinsale over the past eight years, which so far has resulted in an investment of EUR 650 million ($740 million) and the recruitment of 350 additional employees at the site. Lilly has been in Ireland for over 35 years and now employs around 1,000 people in three operations; in Kinsale, Cork City, and Dublin, involved in bulk pharmaceutical (API), biopharmaceutical manufacturing, financial shared services, marketing, and sales.

Source: IDA Ireland